A highly mutated COVID-19 subvariant called BA.3.2, nicknamed “Cicada” for surfacing in large numbers after years of silent evolution, is now spreading quickly across the United States. Laboratory studies show it sidesteps antibodies generated by the most recent vaccine formulations at rates that distinguish it from other circulating strains. The combination of prolonged hidden evolution and significant immune evasion has placed BA.3.2 at the center of public health attention heading into spring 2026.
Why Scientists Call It the “Cicada” Variant
The nickname draws on a biological parallel. Just as periodical cicadas spend years underground before emerging en masse, BA.3.2 appears to have accumulated mutations during a long stretch of undetected circulation. Genomic analysis published in Virus Evolution places BA.3.2 on an extended BA.3-descending evolutionary branch with no intermediate genomes detected, a pattern consistent with prolonged unsampled or isolated evolution. That means the virus likely replicated in a population or host with limited genomic surveillance, picking up dozens of changes before anyone sequenced it.
The variant was first detected in late 2024 in Africa, and its spike protein carries a distinctive set of changes: N-terminal domain (NTD) deletions, an insertion, and multiple amino acid substitutions that set it apart from other Omicron-related subvariants. Those changes are not random scatter. Concentrated in the regions of the spike that antibodies target most aggressively, they suggest strong selective pressure from immune exposure over time. This evolutionary path helps explain why BA.3.2 behaves differently in lab assays than variants that evolved under closer surveillance and more frequent immune “checkpoints.”
Researchers and clinicians have leaned into the metaphor, with some coverage describing BA.3.2 as a newly emerged “Cicada” variant that may have been evolving out of sight for years before suddenly appearing in genomic surveillance data. That long, quiet runway allowed the virus to test many combinations of mutations, keeping the ones that helped it dodge existing immunity while maintaining efficient spread.
How BA.3.2 Evades Vaccine-Generated Antibodies
Two peer-reviewed studies quantify the immune-evasion challenge. Research in The Lancet Infectious Diseases examined sera from people who received an LP.8.1-adapted mRNA booster and found substantially reduced neutralization against BA.3.2 compared with the vaccine-target strain. The drop was large enough for federal health officials to flag BA.3.2 as a variant with clear immune escape potential, even before hospital data could show whether that translated into more severe disease.
A separate study in mBio, published by the American Society for Microbiology, measured neutralizing responses after KP.2-based vaccination and tested those antibodies against BA.3.2 alongside several other Omicron-lineage variants. Using antigenic cartography (a method that maps how far apart variants sit in terms of immune recognition), the researchers showed that BA.3.2 lies at a significant antigenic distance from KP.2. That distance matters because it means antibodies trained on KP.2 have a harder time recognizing and neutralizing BA.3.2 than they do variants that are antigenically closer, even if the underlying lineages look related on a standard phylogenetic tree.
Most early coverage of BA.3.2 focused on individual spike mutations as if each were an independent risk factor. But the more important dynamic may be how those changes interact. When a virus evolves in relative isolation over an extended period, mutations can accumulate in combinations that would be unlikely during rapid, well-surveilled transmission chains. The result is a spike protein that presents a more unfamiliar surface to the immune system than any single mutation would predict. This synergistic effect, rather than any one substitution, likely explains why BA.3.2 shows greater immune evasion in lab assays than some analysts initially expected based on its BA.3 ancestry alone.
CDC Surveillance and U.S. Spread
To monitor BA.3.2’s trajectory, the CDC relies on a multimodal genomic surveillance system that integrates clinical sequencing, wastewater testing, and traveler-based sampling. This approach is designed to catch shifts in variant prevalence earlier than hospital admissions or death data can, especially when a new lineage spreads quickly but causes illness that initially looks similar to other circulating strains.
In its technical assessments, the agency has highlighted BA.3.2’s spike mutations and their likely impact on treatments and diagnostics. Because many of the changes cluster in the NTD and receptor-binding domain, several monoclonal antibody therapies that target those regions may lose potency. By contrast, PCR-based diagnostic tests that focus on more conserved genomic segments are expected to continue detecting infections reliably, even as the spike protein evolves.
What remains uncertain is clinical severity. Surveillance can show that BA.3.2 is gaining ground and escaping antibodies in the lab, but it takes weeks of real-world data to determine whether it causes more hospitalizations or deaths than competing variants. As of late March 2026, no large, controlled cohort studies have reported outcomes for BA.3.2 infections in U.S. populations. For now, public health agencies are inferring risk primarily from immune-evasion metrics, growth advantages over other lineages, and early case reports, rather than definitive evidence that the variant is more or less virulent.
Regional snapshots hint at the speed of its rise. Reporting on national wastewater and sequencing trends indicates that BA.3.2 has rapidly displaced several earlier Omicron descendants, with analyses from academic groups such as Northeastern University describing the recent growth of the “Cicada” lineage as one of the fastest shifts in the viral landscape since the first Omicron wave. Those data points support the lab-based finding that BA.3.2 enjoys a meaningful fitness edge in populations with substantial prior immunity.
What This Means for Everyday Protection
For individuals, the central question is whether current vaccines and prior infections still offer meaningful protection. The answer is nuanced. Neutralization assays capture one layer of defense, the ability of circulating antibodies to block infection at the point of entry. BA.3.2 clearly erodes that layer, which likely translates into more breakthrough infections, including among people who recently received updated boosters.
But immune protection is not all or nothing. T cells and memory B cells, which recognize a wider range of viral fragments than just the spike’s most changeable regions, tend to hold up better against new variants. Those deeper layers of immunity are harder to measure and slower to activate, yet they are crucial for limiting disease severity once infection occurs. Early expert guidance from academic medical centers, including clinicians at Stony Brook Medicine who have outlined practical steps for navigating BA.3.2, emphasizes that even partially matched boosters are expected to reduce the risk of hospitalization and death, particularly for older adults and people with underlying conditions.
That perspective aligns with how public health officials are framing the threat. BA.3.2 may drive new waves of infections and reinfections, but the risk landscape is shaped not only by the virus’s properties but also by population immunity and behavior. High-quality masks remain effective at reducing exposure in crowded indoor settings, regardless of variant. Improving ventilation, testing before gatherings with vulnerable people, and staying home when sick all help blunt transmission, even when a lineage has a notable antibody-escape advantage.
At the same time, the emergence of BA.3.2 underscores the need for more adaptive vaccine strategies. The antigenic distance between BA.3.2 and earlier booster strains such as KP.2 and LP.8.1 suggests that future updates may need to pivot more quickly toward newly dominant lineages, or incorporate broader designs that target multiple conserved viral regions. Researchers are already exploring next-generation platforms aimed at generating more variant-resilient immunity, but those approaches will take time to test and deploy.
For now, experts recommend a pragmatic approach: keep vaccinations current with whatever updated formulation is available, layer in nonpharmaceutical protections during local surges, and pay attention to guidance from health authorities as more data on BA.3.2’s clinical impact emerges. The “Cicada” variant is a reminder that SARS-CoV-2 continues to evolve in ways that can surprise even close observers, but it arrives in a world far better equipped, with vaccines, treatments, and surveillance tools, than at any earlier point in the pandemic.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
